Published on 17 Apr 2024 on Seeking Alpha
Abbott Laboratories (ABT) stock fell even as its Q1 2024 results exceeded estimates despite a contraction in its diagnostics division. Read more here.
Start tracking your investments with Statfolio
Finding "forever" stocks isn't easy. Corporations that can thrive and pay dividends for long peri...
There are many dividend stocks on the market, but few are as prominent as AbbVie (NYSE: ABBV) and...
Buy, hold, rake in solid income. That sounds like a pretty good investing strategy. You only have...
Problems at Cleveland-Cliffs and 3M highlight the dangers when chasing high dividend yields. One ...
Several large-cap MedTech players have already announced first-quarter results. Among them, Abbot...
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just i...
Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a go...
Despite the slight decrease in the target, the firm continues to recommend an Overweight rating o...
Key Insights Abbott Laboratories to hold its Annual General Meeting on 26th of AprilTotal pay for...
Abbott Laboratories (NYSE:ABT) Q1 2024 Earnings Call Transcript April 17, 2024 Abbott Laboratorie...